MG-115 is a potent and reversible proteasome inhibitor, with K_is of 21 nM and 35 nM for 20S and 26S proteasome, respectively. MG-115 specifically inhibit the chymotrypsin-like activity of the proteasome, induces p53-dependent apoptosis.

Solid

Ki: 21 nM (20S proteasome); 35 nM (26 Sproteasome)

MG-115 (0.1-10 μM; 24 h) dose-dependently decreases the viability of HepG2 cells.
MG-115 (0.1-10 μM; 24 h) amplifies the reporter gene expression mediated by CWK₁₈ DNA condensates.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

Room temperature or refrigerated transportation.

-20°C, stored under nitrogen

*In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

• [1]. Rock KL, et, al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell. 1994 Sep 9;78(5):761-71.  [Information]

  [2]. Lopes UG, et, al. p53-dependent induction of apoptosis by proteasome inhibitors. J Biol Chem. 1997 May 16;272(20):12893-6.  [Information]

  [3]. Kim J, et, al. The proteasome metabolizes peptide-mediated nonviral gene delivery systems. Gene Ther. 2005 Nov;12(21):1581-90.  [Information]